ARMATA PHARMACEUTICALS INC (ARMP)
Health Care · Bacteriophage therapeutics / anti-infective biotechnology · Nyse Mkt Llc
Armata is a clinical-stage phage biotech using engineered bacteriophages as a targeted, microbiome-friendly alternative to antibiotics for drug-resistant bacterial infections.
What ARMATA PHARMACEUTICALS INC does
Armata Pharmaceuticals is a late clinical-stage biotechnology company developing high-purity bacteriophage therapeutics to treat antibiotic-resistant and difficult-to-treat bacterial infections. The company has completed three Phase 2 clinical trials for its lead candidates AP-PA02 (targeting Pseudomonas aeruginosa) and AP-SA02 (targeting Staphylococcus aureus), leveraging its proprietary bacteriophage identification, characterization, and cGMP manufacturing capabilities. Bacteriophages represent a differentiated alternative to antibiotics that kill specific bacteria while preserving the healthy human microbiome, addressing the growing global threat of antibiotic resistance.
Themes: ["Antibiotic resistance / bacteriophage therapy","Cystic fibrosis","Non-cystic fibrosis bronchiectasis","Chronic pulmonary infections","Systemic bacterial infections","Alternative to broad-spectrum antibiotics","Microbiome-preserving therapeutics"]
Fundamentals
- Price$4.83 as of 2026-07-09 close
- Market cap$178M as of 2026-07-10
- 1-year return+117.6% as of 2026-07-09 close
- Net margin-5432.8% as of 2026-07-10
- ROE-120.0% as of 2026-07-10
- Debt / equity1.38 as of 2026-07-10
- Revenue growth (YoY)+10.7% as of 2026-07-10
- Beta1.35 as of 2026-07-10
Key risks (from latest filing)
["Clinical development and regulatory approval timelines are uncertain; company must successfully complete Phase 2b/Phase 3 trials and obtain FDA approval for any product commercialization.","Bacteriophage manufacturing at scale remains challenging; the company relies on its Los Angeles cGMP facility and third-party suppliers, with limited control over capacity and performance.","Company is unprofitable with significant accumulated losses and anticipated near-term operating losses; continued ability to raise capital is essential to fund ongoing clinical development."]
Competitors & peers
- Elaphus Therapeutics
- Locus Therapeutics
- Synthetic Biologics
- Intrinsic Therapeutics
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.